Kiniksa Pharmaceuticals International, plc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Kiniksa Pharmaceuticals International, plc (KNSA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $24.36 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-04-28
- Kiniksa Pharmaceuticals International, plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $24.36M.
- Kiniksa Pharmaceuticals International, plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$26.45M, a 179.85% decline year-over-year.
- Kiniksa Pharmaceuticals International, plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $33.12M.
- Kiniksa Pharmaceuticals International, plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$42.10M.
- Kiniksa Pharmaceuticals International, plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$17.98M, a 123.78% decline from fiscal 2024.
- Kiniksa Pharmaceuticals International, plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $75.63M.
- Kiniksa Pharmaceuticals International, plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$14.76M, a 6124.90% decline from fiscal 2022.
- Kiniksa Pharmaceuticals International, plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $245.00K, a 97.02% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-03-31 | $24.36M 10-Q · filed 2026-04-28 | |||
| 2025-12-31 | -$17.98M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | -$8.72M 10-Q · filed 2025-10-28 | |||
| 2025-06-30 | $8.46M 10-Q · filed 2025-07-29 | |||
| 2025-03-31 | -$26.45M 10-Q · filed 2026-04-28 | |||
| 2024-12-31 | $75.63M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | -$10.58M 10-Q · filed 2025-10-28 | |||
| 2024-06-30 | -$8.68M 10-Q · filed 2025-07-29 | |||
| 2024-03-31 | $33.12M 10-Q · filed 2025-04-29 | |||
| 2023-12-31 | -$14.76M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | -$4.89M 10-Q · filed 2024-10-29 | |||
| 2023-06-30 | -$10.15M 10-Q · filed 2024-07-25 | |||
| 2023-03-31 | -$42.10M 10-Q · filed 2024-04-25 | |||
| 2022-12-31 | $245.00K 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $53.29M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$28.16M 10-Q · filed 2023-08-01 | |||
| 2022-03-31 | -$59.15M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $8.22M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $75.94M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $53.91M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $5.82M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $67.11M 10-K · filed 2023-03-02 | |||
| 2020-09-30 | $38.95M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $76.53M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $59.41M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$25.05M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | -$3.17M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $10.83M 10-Q · filed 2020-08-04 | |||
| 2019-03-31 | $10.65M 10-Q · filed 2020-05-04 | |||
| 2018-12-31 | $26.53M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $24.21M 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | $240.33M 10-Q · filed 2019-08-13 | |||
| 2018-03-31 | $175.76M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | -$10.41M 10-K · filed 2019-03-12 | |||
| 2017-09-30 | $12.97M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $23.94M 10-Q · filed 2018-08-06 |